Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription elongation factor A N-terminal and central domain containing 2 (TCEANC2) is a protein-coding gene located on chromosome 1 (human), encoding a protein that is predicted to regulate transcription by RNA polymerase II and to function within the cell nucleus. The principal role appears to be modulation of gene transcription, with broad tissue expression and nuclear localization. While genetic association studies suggest some relevance to diseases, such as breast adenoid cystic carcinoma, TCEANC2 is not currently established as a direct therapeutic target, diagnostic biomarker, or drug-interaction partner. It shares sequence domains similar to factors involved in transcription elongation, but its precise physiological role is not fully characterized; no experimental evidence currently supports direct molecular function or disease-driving effects.
None known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription elongation factor A N-terminal and central domain containing 2 (TCEANC2).